AlenCiken

Itolizumab Reduces Mortality in Patients Hospitalized with COVID

NASDAQ:EQ   Equillium, Inc.
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19

Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon

Biocon has received emergency use approval from Drugs Controller General of India for itolizumab in the treatment of CRS in COVID-19 patients with moderate to severe ARDS

Equillium planning global randomized controlled clinical trial of itolizumab in COVID-19 patients under a U.S. IND

www.globenewswire.co...d-with-COVID-19.html

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。